AirSculpt Technologies Inc

In Stage 2 Advancing, AIRS retains a medium-term bullish bias underpinned by higher highs/lows and support at the rising 50 DMA, but short-term timing is neutral as price pulls back into the 9/21/50 EMA zone. Execution should be deferred around this support range, seeking evidence of acceptance before committing. Primary risk is a decisive break below the 50 DMA and prior higher-low, which would invalidate the bullish outlook.

• ↑Pursuing GLP-1 market, aiming $100M+ revenue from post-treatment aesthetics
• ↑Same-center cases up 21pp YoY, stabilizing core body-contouring revenue
• ↓Earnings yield at -1.94% indicates inability to generate shareholder returns